HOOK News and Press, HOOKIPA Pharma Inc. From 08/10/23

2023-08-10 10:48:29 ET HOOKIPA Pharma press release ( NASDAQ: HOOK ): Q2 GAAP EPS of $0.22 beats by $0.44 . Revenue of $2.7M (-1.8% Y/Y) misses by $2.14M . Net loss was $18.0 million for the three months ended June 30, 2023, compared to a net los...

HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1 st -line setting for advanced head and neck cancer Recruitment ongoing for two Phase 1 clinical trials (HB-300 for advanced prostate cancer and Gilead-partnered HB-400 for chronic hepatit...

NEW YORK and VIENNA, Austria, Aug. 03, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its second quarter 2023 financial ...

2023-06-01 10:07:16 ET Gainers: Nanobiotix ( NBTX ) +17% . Veeva Systems ( VEEV ) +13% . Biohaven ( BHVN ) +12% . Rockwell Medical ( RMTI ) +11% . Quipt Home Medical ( QIPT ) +9% . Losers: Lexicon Pharmaceuticals ( LXRX ...

2023-06-01 02:06:48 ET HOOKIPA Pharma ( NASDAQ: HOOK ) prices an underwritten public offering of ~22.9M common shares and 15,268 shares of its non-voting Series A-2 convertible preferred stock. The public offering price of each share of common stock is $1.31 and the public...

NEW YORK and VIENNA, Austria, May 31, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the pricing of an underwritten public offering of 22,900...

2023-05-31 19:47:53 ET This week has seen the stock market flip-flop, including the volatile world of penny stocks . Investors, especially those interested in high-risk, high-reward low-priced stocks, are attentively tracking the developments in Washington. The impending vote on the deb...

HB-200 in combination with pembrolizumab doubled the objective response rate of 1 st -line pembrolizumab for patients with recurrent/metastatic head and neck cancer HOOKIPA is preparing to start a pivotal trial of HB-200 in combination with pembrolizumab as 1 st -line trea...

2023-05-11 09:32:47 ET HOOKIPA Pharma press release ( NASDAQ: HOOK ): Q1 GAAP EPS of -$0.27 misses by $0.03 . Revenue of $3.17M (+120.1% Y/Y) misses by $1.34M . For further details see: HOOKIPA Pharma GAAP EPS of -$0.27 misses by $0.03, revenue of $3.17M ...

HOOKIPA on track to report Phase 2 data on HB-200 for head and neck cancer in combination with pembrolizumab in 2Q 2023 Phase 1 clinical trials initiated for two programs (HB-300 for advanced prostate cancer and Gilead-partnered HB-400 for chronic hepatitis B) HB-700 for KRAS-muta...